ArticleJCEM case reports2023
Two Cases of Frontal Variation of Idiopathic Calvarial Thinning-Therapeutic Effect of Denosumab and Romosozumab.
Article in JCEM case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
- Idiopathic calvarial thinning mimicking en coup de sabre deformity.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic calvarial thinning is a rare condition that causes progressive, painless thinning of the skull bones without systemic disease. We present 2 cases of idiopathic calvarial thinning involving the bifrontal region. Both patients exhibited forehead depression and had normal biochemical tests except for mild vitamin D deficiency. The first patient received treatment with denosumab for 3 years, showing no further progression of the skull thinning. The second patient was treated with denosumab for 3 years, followed by romosozumab for 1 year, resulting in no further progression and even slight recovery of the skull thickness. These cases demonstrate that idiopathic calvarial thinning can involve the bifrontal region and highlight the favorable treatment and prognosis with denosumab or romosozumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.